Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial. CD-001, the ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of ...

A research team consisting of Professor Dong Sung Kim, Professor Anna Lee, and Dr. Jaeseung Youn from the Department of ...

When studying the spread of cancer or the behavior of a virus like the one that causes COVID-19, the irony is that working ...